$599

Insulet Q1 ’23 Earnings and Organizational Changes; Tidepool Secures Funding to Support Tidepool Loop for Android

Three cardiometabolic-related news items have been observed: Insulet hosted its Q1 ’23 earnings call (view press release; slides) and provided updates to its commercial and R&D activities; in a separate press release, Insulet announced a new organizational structure, effective July 1, 2023 (view press release); and Tidepool announced it has secured funding to develop Tidepool Loop for Android devices (view press release). Below, FENIX provides highlights and insights into the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.